Calidi Biotherapeutics announced it will present new preclinical data on its lead virotherapy program CLD-401 and its In Situ T-cell engager platform at the ESMO Congress 2026 in Madrid. CLD-401 shows promising tumor-targeting and immune activation effects in animal models, including high tumor eradication rates. The presentations will also cover CLD-501 and CLD-502 candidates designed to enhance T-cell activity within tumors. These advances highlight Calidi's innovative RedTail platform's potential to improve cancer treatment by delivering genetic medicines directly to tumors, with ongoing efforts to expand clinical development and partnerships.
Calidi Biotherapeutics' upcoming presentation at ESMO Congress 2026 provides context for readers interested in health sector developments. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:01 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 73 rose and 47 fell. Notable movers include AMLX at USD 26.86 (+1.97%), RLAY at USD 16.59 (+1.90%), and BFLY at USD 7.38 (+1.86%), with AMLX showing the highest typical hold time of 16 days.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
